Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - gripp, inimene - gripi vaktsiinid, gripi, live nõrgenenud - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. fluenz tetra kasutamine peaks põhinema ametlikel soovitustel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolaktoon - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - muudetud live veiste viiruslik kõhulahtisus viiruse tüüp 1, mitte-cytopathic algtüve ke-9 ja modifitseeritud live veiste viiruslik kõhulahtisus virus tüüp 2, mitte-cytopathic algtüve ny-93 - immunoloogilised ravimid jaoks bovidae, live viral vaccines - aktiivse immuniseerimise veiseid alates 3 kuu vanusest vähendada hyperthermia ja vähendada vähendada leukotsüütide arv, mis on põhjustatud veiste viiruslik kõhulahtisus viiruse (bvdv-1 ja bvdv-2), ja vähendada viiruse levikuga ja viraemia põhjustatud bvdv-2. veiste aktiivseks immuniseerimiseks bvdv-1 ja bvdv-2 vastu, et vältida püsivalt nakatunud vasikate sündi, mis on põhjustatud transplatsentaarsest infektsioonist.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae tüvi ms-h - immunoloogilised ravimid jaoks linnud, live bacterial vaccines - kana - aktiivse immuniseerimise tulevikus broiler kanade aretaja, tulevikus kiht kasvataja kanad ja tulevikus kiht kanad, et vähendada õhu-sac kahjustused ja vähendada munade arv ebanormaalne shell moodustamine põhjustatud mycoplasma synoviae.

Euroopa Liit - eesti - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinantse türgi herpesvirus, tüvi vhvt013-69, live - immunoloogilised ravimid jaoks linnud, kodukana, immunoloogilised ravimid - embryonated eggs; chicken - aktiivse immuniseerimise kanade:selleks, et ära hoida suremust ja vähendada kliinilisi tunnuseid ja kahjustused nakkav haiguse bursal. vähendada suremust, kliinilisi tunnuseid ja kahjustuste marek tõbi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international b.v. - raku seotud live rekombinantse türgi herpesvirus (tüvi hvp360), väljendades fusion valk nd viiruse ja vp2 valgu kohta ibd viirus - lindude herpes viirus (marek tõbi) + lindude nakkav bursal haiguse viiruse (gumboro haigus) + newcastle ' i haiguse viiruse/paramyxovirus - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaktsiinid - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 ja 4. kasutada dengvaxia peab olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfate - kõhu kasvajaid - antineoplastilised ained - vitrakvi nagu monotherapy on näidustatud ravi täiskasvanud ja pediaatriliste patsientide tahkete kasvajate, et kuvada neurotroofse retseptori türosiini kinase (ntrk) geen fusion,kes on haigus, mis on lokaalselt kaugelearenenud, metastaatilise või kui kirurgiline resektsioon tõenäoliselt põhjustada haigestumist, andwho on rahuldavat ravi valikud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

bavarian nordic a/s - vibrio cholerae, tüvi cvd 103-hgr, live - cholera - vaktsiinid - vaxchora is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children aged 2 years and older. selle vaktsiini tuleb kasutada vastavalt ametlikele soovitustele.